1. Home
  2. LEGN vs STUB Comparison

LEGN vs STUB Comparison

Compare LEGN & STUB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • STUB
  • Stock Information
  • Founded
  • LEGN 2014
  • STUB 2000
  • Country
  • LEGN United States
  • STUB United States
  • Employees
  • LEGN N/A
  • STUB N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • STUB Services-Misc. Amusement & Recreation
  • Sector
  • LEGN Health Care
  • STUB Consumer Discretionary
  • Exchange
  • LEGN Nasdaq
  • STUB Nasdaq
  • Market Cap
  • LEGN 6.3B
  • STUB 6.4B
  • IPO Year
  • LEGN 2020
  • STUB 2025
  • Fundamental
  • Price
  • LEGN $32.30
  • STUB $19.55
  • Analyst Decision
  • LEGN Strong Buy
  • STUB Buy
  • Analyst Count
  • LEGN 12
  • STUB 10
  • Target Price
  • LEGN $70.82
  • STUB $27.78
  • AVG Volume (30 Days)
  • LEGN 1.5M
  • STUB 3.7M
  • Earning Date
  • LEGN 11-11-2025
  • STUB 11-26-2025
  • Dividend Yield
  • LEGN N/A
  • STUB N/A
  • EPS Growth
  • LEGN N/A
  • STUB N/A
  • EPS
  • LEGN N/A
  • STUB N/A
  • Revenue
  • LEGN $796,838,000.00
  • STUB $1,795,096,000.00
  • Revenue This Year
  • LEGN $70.27
  • STUB $8.27
  • Revenue Next Year
  • LEGN $50.28
  • STUB $54.04
  • P/E Ratio
  • LEGN N/A
  • STUB N/A
  • Revenue Growth
  • LEGN 74.75
  • STUB 18.61
  • 52 Week Low
  • LEGN $27.34
  • STUB $16.11
  • 52 Week High
  • LEGN $47.79
  • STUB $27.89
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 45.99
  • STUB N/A
  • Support Level
  • LEGN $31.44
  • STUB N/A
  • Resistance Level
  • LEGN $32.59
  • STUB N/A
  • Average True Range (ATR)
  • LEGN 1.36
  • STUB 0.00
  • MACD
  • LEGN 0.11
  • STUB 0.00
  • Stochastic Oscillator
  • LEGN 37.97
  • STUB 0.00

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About STUB StubHub Holdings Inc. Class A Common Stock

Stubhub Holdings Inc is an online marketplace for secondary ticket buy and selling.

Share on Social Networks: